Company / Shareholders' Equity
Sana Biotechnology, Inc. Shareholders' Equity History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$250.5M
FY2024
5-year range
-$421.2M / $728.5M
FY2020-FY2024
Trend
-12.9%
vs FY2023
Sector context
#146 of 213
Health Care
What the data says
At $251M, Sana Biotechnology, Inc.'s shareholders' equity ranks #146 of 213 in the Health Care sector. Shareholders' Equity has declined for 3 consecutive years, from $729M in FY2021 to $251M in FY2024.
Based on SEC 10-K filings.
$251M in FY2024 with a 3-year CAGR of -29.9%.
Declined from $499M to $251M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -29.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#146 of 213 in Health CareTop 69% of 213This company $250.5M Sector average $2.5B
▼
-90.2% below sector average
Key checks
Key Insights
- Sana Biotechnology, Inc.'s shareholders' equity has declined for 3 consecutive years.
- 3-year CAGR of -29.9%, indicating a declining trend.
- In FY2024, shareholders' equity decreased 12.9% year-over-year.
- Ranks #146 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $250.5M | -12.9% |
| FY2023 | $287.5M | -42.4% |
| FY2022 | $499.3M | -31.5% |
| FY2021 | $728.5M | +273.0% |
| FY2020 | -$421.2M | -195.5% |
| FY2019 | -$142.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026